During the last budget period, the Cancer Center has introduced sweeping changes that affected its administrative infrastructure, decision-making process, scientific realignment of Programs and Shared Resources and expansion of educational and mentoring activities. These changes were directed by a comprehensive, inclusive and transparent strategic planning process that involved all scientific, administrative and educational stakeholders in the Cancer Center. A combination of internal Center-wide consultative sessions, including annual scientific and planning retreats, and in-depth feedback by a newly configured Cancer Center External Advisory Board, contributed to make the strategic planning process a successful endeavor, creating a set of strategic directives {Strategic comparatives) that guided the comprehensive reorganization of the Cancer Center during the last budget period. The resulting 2012 Cancer Center Strategic Plan refined the Center's long-term vision in the continuum of basic, translational and patient-oriented research, streamlined operation and decision-making, and identified concrete opportunities for scientific expansion, thematic faculty recruitment and development of new, multidisciplinary research themes. Overall, the consultative tools that enabled the strategic planning process will continue to provide a fundamental asset for the Cancer Center in the next budget period, ensuring a nimble and research-oriented administrative infrastructure, opportunity-driven decision-making, comprehensive feedback from external advisors and dynamic refinement of research priorities and scientific themes. Building on the successful growth ofthe Cancer Center in the last project period in terms of collaborative contributions and cancer-focused research funding, these planning and consultative processes as supported by the CCSG budget will continue to play an indispensable role in further advancing the cancer research agenda during the upcoming faculty and facility expansion.

Public Health Relevance

The Cancer Center has developed a comprehensive, all-encompassing consultative platform ideally positioned to chart new research directions, identify opportunities for multidisciplinary and collaborative science and guide the process of scientific discovery along the continuum of basic, translational and patient oriented cancer research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112

Showing the most recent 10 out of 685 publications